A dose finding human experimental infection study with SARS-CoV-2 Omicron BA.5 subvariant in healthy volunteers immunologically experienced against SARS-CoV-2 (COV-CHIM02)

Research summary

The purpose of this study is to evaluate the safety and human clinical response to SARS-CoV-2 challenge with the omicron variant virus, in previously SARS-CoV-2 vaccinated people. We aim to establish the optimal challenge dose that causes re-infection and identify the lowest level of infectious dose necessary to produce viral replication in the upper respiratory tract of research volunteers while minimising risk of disease progression. Investigators aim to achieve an infection model which results in no symptoms, or symptoms no more severe than the common mild response of healthy people of the same age within the general population. The study will recruit healthy volunteers between the ages of 18 and 40 years, who will attend a 2 week quarantine stay and be followed up by the study team for 6 months. Enrolment may be at one of three study sites.

Principal Investigator

Prof Helen McShane

Contact us

Email: vaccinetrials@ndm.ox.ac.uk

IRAS number

338445